Physician profile
Bud L Wolfson
NPI 1699743807
$8,533.37
in general payments reported to CMS, 2019-2025
45 companies · $929 in 2025
The $929 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $1,050 · 2021: $2,007 · 2022: $1,222 · 2023: $1,282 · 2024: $903 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,042 · Education: $72.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,042.06 |
| Education | $72.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,106.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,051.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $774.23 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $690.26 | 2019-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $490.02 | 2019-2025 | |
| Amgen INC. | $419.51 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $316.44 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amarin Pharma, INC. | $278.32 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.25 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $262.42 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $240.81 | 2019-2025 | Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $208.19 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $187.76 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.74 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $143.95 | 2024-2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bud Wolfson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.